Glukóza B. Braun

Glukóza B. Braun is a sterile solution for injection containing glucose monohydrate as the active ingredient. It is supplied as a parenteral carbohydrate solution in a ready‑to‑use intravenous formulation, marketed in the European Union. The product is prescribed by healthcare professionals for rapid glucose supplementation and fluid replacement in clinical settings. It is available in concentrations for intravenous administration and is classified as an Rx excipient used in nutrition regimens.

Glukóza B. Braun is indicated for clinical situations that require rapid elevation of blood glucose or provision of carbohydrate calories intravenously.

- Treatment of acute hypoglycemia when oral glucose is not feasible. - Component of parenteral nutrition formulas to supply energy. - Fluid and electrolyte replacement in patients unable to tolerate oral intake. - Support during surgical procedures or critical care when glucose infusion is required. - Adjunctive therapy for certain metabolic disorders under specialist supervision. - Dilution and administration as part of intravenous fluid therapy to maintain caloric balance in long‑term hospitalized patients.

The safety profile of Glukóza B. Braun reflects the expected pharmacologic response to intravenous glucose and includes both frequent mild reactions and rare serious events.

Common: - Transient increase in blood glucose concentration. - Mild infusion site discomfort or erythema. - Electrolyte shifts such as low potassium (hypokalemia) secondary to insulin release. - Nausea or abdominal discomfort in susceptible individuals. - Headache or dizziness. - Transient feeling of warmth or flushing during infusion.

Serious: - Severe hyperglycemia leading to osmotic diuresis or ketoacidosis. - Anaphylactic or severe hypersensitivity reaction (rash, bronchospasm, hypotension). - Fluid overload causing pulmonary edema, especially in patients with cardiac or renal impairment. - Severe electrolyte disturbances such as profound hypokalemia or hypernatremia.

When administering Glukóza B. Braun, clinicians should observe specific precautions to minimize risks related to glucose overload, fluid balance, and patient-specific conditions.

- Assess baseline blood glucose and adjust infusion rate to avoid hyperglycemia. - Evaluate renal and cardiac function before large‑volume administration to prevent fluid overload. - Monitor serum electrolytes, especially potassium and sodium, during and after infusion. - Use aseptic technique; discard any solution that appears discolored or contains particles. - Consider contraindications such as known hypersensitivity to glucose solutions. - Adjust dose in patients receiving insulin or other glucose‑lowering agents. - Avoid rapid infusion in neonates and infants unless specifically indicated.

Glukóza B. Braun may interact with other medications that affect glucose metabolism, fluid status, or electrolyte balance, requiring careful management.

Avoid: - Co‑administration with high‑dose insulin boluses without monitoring can cause severe hypoglycemia. - Simultaneous infusion of hypertonic saline solutions may exacerbate hypernatremia.

Use with caution: - Concurrent use of diuretics may increase the risk of electrolyte disturbances. - Patients receiving catecholamines or glucocorticoids may experience altered glucose requirements. - Fluid replacement therapy in heart failure patients should be titrated to avoid volume overload. - Parenteral nutrition regimens containing other carbohydrate sources should be balanced to prevent excess caloric intake.